Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Satoshi Suzuki, Moriya Iwaizumi, Stephanie Tseng-Rogenski, Yasushi Hamaya, Hiroaki Miyajima, Shigeru Kanaoka, Ken Sugimoto & John M. Carethers. (2016) Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status. Cancer Biology & Therapy 17:7, pages 760-768.
Read now
Read now
Articles from other publishers (28)
Leonora W. de Boo, Katarzyna Jóźwiak, Heikki Joensuu, Henrik Lindman, Susanna Lauttia, Mark Opdam, Charlaine van Steenis, Wim Brugman, Roelof J. C. Kluin, Philip C. Schouten, Marleen Kok, Petra M. Nederlof, Michael Hauptmann & Sabine C. Linn. (2022) Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients. British Journal of Cancer 126:10, pages 1401-1409.
Crossref
Crossref
David Mas-Ponte, Marcel McCullough & Fran Supek. (2022) Spectrum of DNA mismatch repair failures viewed through the lens of cancer genomics and implications for therapy. Clinical Science 136:5, pages 383-404.
Crossref
Crossref
Helena de Castro e Gloria, Laura Jesuíno Nogueira, Patrícia Bencke Grudzinski, Paola Victória da Costa Ghignatti, Temenouga Nikolova Guecheva, Natalia Motta Leguisamo & Jenifer Saffi. (2021) Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells. BMC Cancer 21:1.
Crossref
Crossref
Peng-Chan Lin, Yu-Min Yeh, Ren-Hao Chan, Bo-Wen Lin, Po-Chuan Chen, Chien-Chang Pan & Meng-Ru Shen. (2021) Sequential and co-occurring DNA damage response genetic mutations impact survival in stage III colorectal cancer patients receiving adjuvant oxaliplatin-based chemotherapy. BMC Cancer 21:1.
Crossref
Crossref
Chinmayee Sethy & Chanakya Nath Kundu. (2021) 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. Biomedicine & Pharmacotherapy 137, pages 111285.
Crossref
Crossref
Larissa Costa de Almeida, Felipe Antunes Calil, João Agostinho Machado-Neto & Leticia Veras Costa-Lotufo. (2021) DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy. Cancer Genetics 252-253, pages 6-24.
Crossref
Crossref
John M. Carethers. 2021. Novel Approaches to Colorectal Cancer. Novel Approaches to Colorectal Cancer
197
229
.
Sonal Gupta, Manisha Mathur, Beiping Miao, Prashanth Suravajhala & Obul Reddy Bandapalli. 2021. Colon Cancer Diagnosis and Therapy. Colon Cancer Diagnosis and Therapy
209
223
.
Jaime A. Oliver, Raúl Ortiz, Cristina Jiménez-Luna, Laura Cabeza, Gloria Perazzoli, Octavio Caba, Cristina Mesas, Consolación Melguizo & Jose Prados. (2020) MMR-proficient and MMR-deficient colorectal cancer cells: 5-Fluorouracil treatment response and correlation to CD133 and MGMT expression. Journal of Biosciences 45:1.
Crossref
Crossref
Tomohiro Sugiyama, Moriya Iwaizumi, Masanao Kaneko, Shinya Tani, Mihoko Yamade, Yasushi Hamaya, Takahisa Furuta, Hiroaki Miyajima, Satoshi Osawa, Satoshi Baba, Masato Maekawa & Ken Sugimoto. (2020) DNA mismatch repair is not disrupted in stage 0 colorectal cancer resected using endoscopic submucosal dissection. Oncology Letters 20:3, pages 2435-2441.
Crossref
Crossref
Somayeh Mohammadpour, Hamed R. Goodarzi, Mojtaba Jafarinia, Mohammad A. Porhoseingholi & Ehsan Nazemalhosseini‐Mojarad. (2019) EMAST status as a beneficial predictor of fluorouracil‐based adjuvant chemotherapy for Stage II/III colorectal cancer. Journal of Cellular Physiology 235:4, pages 3604-3611.
Crossref
Crossref
Sona Vodenkova, Tomas Buchler, Klara Cervena, Veronika Veskrnova, Pavel Vodicka & Veronika Vymetalkova. (2020) 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacology & Therapeutics 206, pages 107447.
Crossref
Crossref
Maide Ö. Raeker, Jovan Pierre-Charles & John M. Carethers. (2020) Tetranucleotide Microsatellite Mutational Behavior Assessed in Real Time: Implications for Future Microsatellite Panels. Cellular and Molecular Gastroenterology and Hepatology 9:4, pages 689-704.
Crossref
Crossref
Nicole M. Reilly, Luca Novara, Federica Di Nicolantonio & Alberto Bardelli. (2019)
Exploiting
DNA
repair defects in colorectal cancer
. Molecular Oncology 13:4, pages 681-700.
Crossref
Crossref
Satoshi Suzuki, Moriya Iwaizumi, Hidetaka Yamada, Tomohiro Sugiyama, Yasushi Hamaya, Takahisa Furuta, Shigeru Kanaoka, Haruhiko Sugimura, Hiroaki Miyajima, Satoshi Osawa, John M. Carethers & Ken Sugimoto. (2017)
MBD4
frameshift mutation caused by DNA mismatch repair deficiency enhances cytotoxicity by trifluridine, an active antitumor agent of TAS-102, in colorectal cancer cells
. Oncotarget 9:14, pages 11477-11488.
Crossref
Crossref
Liming Xu, Guilian Cheng, Yi Lu & Shaofeng Wang. (2017) An active molecule from Pulsatilla chinensis, Pulsatilla saponin A, induces apoptosis and inhibits tumor growth of human colon cancer cells without or with 5-FU. Oncology Letters 13:5, pages 3799-3802.
Crossref
Crossref
John M. Carethers. (2017) Microsatellite Instability Pathway and EMAST in Colorectal Cancer. Current Colorectal Cancer Reports 13:1, pages 73-80.
Crossref
Crossref
John M. Carethers. (2016) GRG Profiles: John M. Carethers. Digestive Diseases and Sciences 61:6, pages 1429-1435.
Crossref
Crossref
John M. Carethers & Barbara H. Jung. (2015) Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. Gastroenterology 149:5, pages 1177-1190.e3.
Crossref
Crossref
Yasushi Hamaya, Carla Guarinos, Stephanie S. Tseng-Rogenski, Moriya Iwaizumi, Ritabrata Das, Rodrigo Jover, Antoni Castells, Xavier Llor, Montserrat Andreu & John M. Carethers. (2015) Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal Cancer. PLOS ONE 10:5, pages e0127591.
Crossref
Crossref
John M Carethers. (2015) Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer. World Journal of Gastroenterology 21:31, pages 9253.
Crossref
Crossref
Veronika Vymetalkova, Barbara Pardini, Fabio Rosa, Cornelia Di Gaetano, Jan Novotny, Miroslav Levy, Tomas Buchler, Jana Slyskova, Ludmila Vodickova, Alessio Naccarati & Pavel Vodicka. (2014) Variations in mismatch repair genes and colorectal cancer risk and clinical outcome. Mutagenesis 29:4, pages 259-265.
Crossref
Crossref
John M. Carethers. (2014) DNA Testing and Molecular Screening for Colon Cancer. Clinical Gastroenterology and Hepatology 12:3, pages 377-381.
Crossref
Crossref
De-Qing Zhang, Qiang Guo, Jian-Hong Zhu & Wei-Chang Chen. (2013) Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer. World Journal of Surgical Oncology 11:1.
Crossref
Crossref
Moriya Iwaizumi, Stephanie Tseng-Rogenski & John M. Carethers. (2013) Acidic tumor microenvironment downregulates hMLH1 but does not diminish 5-fluorouracil chemosensitivity. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 747-748, pages 19-27.
Crossref
Crossref
Jae Myung Park, Shengbing Huang, David Tougeron & Frank A. Sinicrope. (2013) MSH3 Mismatch Repair Protein Regulates Sensitivity to Cytotoxic Drugs and a Histone Deacetylase Inhibitor in Human Colon Carcinoma Cells. PLoS ONE 8:5, pages e65369.
Crossref
Crossref
Kerry M. Bauer, Paul A. Lambert & Amanda B. Hummon. (2012)
Comparative label‐free
LC
‐
MS
/
MS
analysis of colorectal adenocarcinoma and metastatic cells treated with 5‐fluorouracil
. PROTEOMICS 12:12, pages 1928-1937.
Crossref
Crossref
Juan Cristóbal Conde-Pérezprina, Miguel Ángel León-Galván & Mina Konigsberg. (2012) DNA Mismatch Repair System: Repercussions in Cellular Homeostasis and Relationship with Aging. Oxidative Medicine and Cellular Longevity 2012, pages 1-9.
Crossref
Crossref